XML 85 R66.htm IDEA: XBRL DOCUMENT
v3.25.0.1

Option Agreements and License Agreements (Details) - USD ($) $ in Millions | 11 Months Ended | 12 Months Ended
--- | --- | ---
Dec. 31, 2024 | Dec. 31, 2023
Option Agreements and License Agreements [Line Items] |  |
Expenses | $ 42.0 |
Regulatory Milestones Member [Member] |  |
Option Agreements and License Agreements [Line Items] |  |
Non-refundable milestone payments | $ 10.0 |
Paruka Warrant Obligation [Member] |  |
Option Agreements and License Agreements [Line Items] |  |
Warrant purchase percentage | 1.00% |
Paragon [Member] | Clinical Development Milestones [Member] |  |
Option Agreements and License Agreements [Line Items] |  |
Non-refundable milestone payments | $ 12.0 |
Paragon [Member] | Regulatory Milestones Member [Member] |  |
Option Agreements and License Agreements [Line Items] |  |
Non-refundable milestone payments | $ 10.0 |
Paragon [Member] | Antibody Products [Member] |  |
Option Agreements and License Agreements [Line Items] |  |
Royalty payable on product sales, description | low single-digit percentage royalty for antibody products |
Nomination Of A Development Candidate [Member] | Paragon [Member] |  |
Option Agreements and License Agreements [Line Items] |  |
Non-refundable milestone payments | $ 1.5 |
ORKA-001 License Agreement [Member] | Paragon [Member] | Clinical Development Milestones [Member] |  |
Option Agreements and License Agreements [Line Items] |  |
Non-refundable milestone payments | 12.0 |
ORKA-002 License Agreement [Member] | Paragon [Member] | Clinical Development Milestones [Member] |  |
Option Agreements and License Agreements [Line Items] |  |
Non-refundable milestone payments | $ 12.0 |
ORKA-001 [Member] |  |
Option Agreements and License Agreements [Line Items] |  |
Development costs, percentage | 50.00% |
Research and development expenses | $ 13.5 |
ORKA-001 [Member] | Paragon [Member] |  |
Option Agreements and License Agreements [Line Items] |  |
Initiation fee | 0.8 |
ORKA-001 [Member] | Paragon [Member] | First Dosing of Human Patient in Phase1Trial Milestone [Member] |  |
Option Agreements and License Agreements [Line Items] |  |
Non-refundable milestone payments | 2.5 |
ORKA-001 [Member] | Related Party [Member] |  |
Option Agreements and License Agreements [Line Items] |  |
Accounts payable and other current liabilities | 2.8 |
ORKA-001 [Member] | Research and Development Expense [Member] | Paragon [Member] | First Dosing of Human Patient in Phase1Trial Milestone [Member] |  |
Option Agreements and License Agreements [Line Items] |  |
Milestone consideration paid | 2.5 |
ORKA-001 [Member] | Research and Development Expense [Member] | Paragon [Member] | Achievement Of Development Candidate [Member] |  |
Option Agreements and License Agreements [Line Items] |  |
Milestone consideration paid | $ 1.5 |
ORKA-002 [Member] | Paruka Warrant Obligation [Member] |  |
Option Agreements and License Agreements [Line Items] |  |
Warrant purchase percentage | 1.00% |
ORKA-002 [Member] | Paragon [Member] |  |
Option Agreements and License Agreements [Line Items] |  |
Research and development expenses | $ 7.8 |
Development costs |  | $ 3.3
Research initial fees | 0.8 |
ORKA-002 [Member] | Paragon [Member] | First Dosing of Human Patient in Phase1Trial Milestone [Member] |  |
Option Agreements and License Agreements [Line Items] |  |
Non-refundable milestone payments | 2.5 |
ORKA-002 [Member] | Related Party [Member] |  |
Option Agreements and License Agreements [Line Items] |  |
Accounts payable and other current liabilities | 2.7 |
ORKA-002 [Member] | Research and Development Expense [Member] | Paragon [Member] | Achievement Of Development Candidate [Member] |  |
Option Agreements and License Agreements [Line Items] |  |
Milestone consideration paid | $ 1.5 |

X
- Definition class of warrant or right to purchase percentage of outstanding diluted stock maximum. + References No definition available. + Details
Name: | orka_ClassOfWarrantOrRightToPurchasePercentageOfOutstandingDilutedStockMaximum
Namespace Prefix: | orka_
Data Type: | dtr:percentItemType
Balance Type: | na
Period Type: | duration

X
- Definition Percentage of development costs. + References No definition available. + Details
Name: | orka_DevelopmentCostsPercentage
Namespace Prefix: | orka_
Data Type: | dtr:percentItemType
Balance Type: | na
Period Type: | duration

X
- Definition The milestone consideration paid amount. + References No definition available. + Details
Name: | orka_MilestoneConsiderationPaid
Namespace Prefix: | orka_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Non-refundable milestone payments. + References No definition available. + Details
Name: | orka_NonRefundableMilestonePayments
Namespace Prefix: | orka_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Represent the amount of development costs. + References No definition available. + Details
Name: | orka_OtherDevelopmentCost
Namespace Prefix: | orka_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition The amount of research initial fees. + References No definition available. + Details
Name: | orka_ResearchInitialFee
Namespace Prefix: | orka_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Royalty payable on product sales, description. + References No definition available. + Details
Name: | orka_RoyaltyPayableOnProductSales
Namespace Prefix: | orka_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | instant

X
- Definition Amount of obligations incurred classified as other, payable within one year or the normal operating cycle, if longer. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(19)(a)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details
Name: | us-gaap_AccountsPayableOtherCurrent
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 808 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479402/808-10-50-1 + Details
Name: | us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Amount of expense classified as other. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(6)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(4)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2 + Details
Name: | us-gaap_OtherExpenses
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Amount of other research and development expense. + References Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 730 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482916/730-10-50-1 + Details
Name: | us-gaap_OtherResearchAndDevelopmentExpense
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Amount of cash outflow for fees classified as other. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 25 -Subparagraph (g) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-25 + Details
Name: | us-gaap_PaymentsForFees
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Details
Name: | us-gaap_LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis=orka_RegulatoryMilestonesMemberMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_ClassOfWarrantOrRightAxis=orka_ParukaWarrantObligationMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_CounterpartyNameAxis=orka_ParagonMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis=orka_ClinicalDevelopmentMilestonesMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis=orka_AntibodyProductsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=orka_NominationOfADevelopmentCandidateMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=orka_ORKAZeroZeroOneLicenseAgreementMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=orka_ORKAZeroZeroTwoLicenseAgreementMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=orka_ORKAZeroZeroOneMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis=orka_FirstDosingOfHumanPatientInPhaseOneTrialMilestoneMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_RelatedPartyTransactionAxis=us-gaap_RelatedPartyMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis=orka_AchievementOfDevelopmentCandidateMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=orka_ORKAZeroZeroTwoMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |